Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD) will hold a business update conference call and webcast on Wednesday, November 12, 2025 at 8:30 AM ET. Management will include Lishan Aklog, M.D., chairman and CEO, who will provide a business update and growth strategy overview, and Dennis McGrath, CFO, who will discuss third quarter 2025 financial results. The webcast will be available in the investor relations section at luciddx.com. U.S. dial-in is 1-800-836-8184; international dial-in is 1-646-357-8785; ask the operator for the conference call name "Lucid Diagnostics Business Update" to join. A replay will be available for 30 days on the investor relations site.

Conference Call and Webcast at 8:30 AM Eastern Time

NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-12-2025-302597099.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) scheduled to hold its business update call?

The business update call is scheduled for Wednesday, November 12, 2025 at 8:30 AM ET.

Who will speak on the Lucid Diagnostics (LUCD) November 12, 2025 call?

Lishan Aklog, M.D. (chairman and CEO) and Dennis McGrath (CFO) will present.

Will Lucid Diagnostics (LUCD) discuss financial results on the November 12, 2025 call?

Yes. The CFO will discuss third quarter 2025 financial results during the call.

How can investors access the Lucid Diagnostics (LUCD) webcast on November 12, 2025?

Access the live webcast via the investor relations section at luciddx.com.

What are the dial-in numbers to join the Lucid Diagnostics (LUCD) conference call by phone?

U.S. callers: 1-800-836-8184; international callers: 1-646-357-8785; provide the conference name "Lucid Diagnostics Business Update".

Will a replay of the Lucid Diagnostics (LUCD) November 12, 2025 call be available?

Yes. A replay will be available for 30 days on the investor relations section of luciddx.com.